3.9 Editorial Material

Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer

Journal

EUROPEAN UROLOGY SUPPLEMENTS
Volume 7, Issue 10, Pages 618-626

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.eursup.2008.08.002

Keywords

Bladder cancer risk factors; Epidemiology; Grading; Non-muscle invasive bladder cancer; Risk stratification; Staging

Ask authors/readers for more resources

Context: Understanding the epidemiology and risk factors for non-muscle invasive bladder cancer (NMIBC) can assist: in the prevention and early detection of the disease. Furthermore, staging, grading, and risk stratification are critical for determining the most appropriate management strategies for NMIBC based on risk of recurrence and progression. Objective: To provide community urologists with an overview of the epidemiology of NMIBC as well as current approaches to staging, grading, and risk stratification. Evidence acquisition: A committee of internationally renowned leaders in bladder cancer management, known as the International Bladder Cancer Group (IBCG), identified current key influencing guidelines and published English-language literature related to file epidemiology, staging, and grading of NMIBC available as of March 2008. The IBCG met on four occasions to review the main findings of the identified literature and the current clinical practice guidelines of the European Association of Urology (EAU), the First International Consultation on Bladder Tumors (FICBT), the National Comprehensive Cancer Network (NCCN), and the American Urological Association (AUA). Evidence synthesis: Based on this review, the IBCG provided a summary on the epidemiology of NMIBC and recommendations for the staging, grading, and risk stratification of the disease. Conclusions: Urologists should record the smoking habits of patients and monitor for possible occupational exposure to urothelial carcinogens. The tumour-node-metastases (TNM) classification for tumour staging and both the World Health Organization (WHO) 1973 and 2004 grading systems should be applied for appropriate staging and grading of NMIBC. Urologists should also consider the use of the European Organisation for Research and Treatment of Cancer (EORTC) risk tables for risk stratification of NMIBC based on risk of disease recurrence and progression. (C) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available